FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 331:31-38 July 7, 1994 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Sotalol hydrochloride is a potent noncardioselective -adrenergic-blocking agent devoid of intrinsic sympathomimetic and membrane-stabilizing actions^1,2,3,4,5,6. Unlike other -adrenergic-blocking drugs, sotalol (4-(2-isopropylamino-1-hydroxyethyl) methanesulfonanilide hydrochloric acid) prolongs the duration of action potentials recorded in cardiac tissue, increases the refractory period, and lengthens the QT interval on the surface electrocardiogram^1,2. It is an effective antiarrhythmic and antifibrillatory agent in patients with various cardiac-rhythm disorders. The drug has been used extensively in Europe and has recently been approved for marketing in the United States as an agent for oral use in patients with life-threatening ventricular tachyarrhythmias.

-Adrenergic Antagonism

Sotalol is marketed as the racemic . . . [Full Text of this Article]

Effects on Membrane Currents

Electrophysiologic and Antiarrhythmic Effects

Inotropic Effects

Clinical Pharmacokinetics and Dose Schedules

Sotalol Therapy after Myocardial Infarction

Efficacy of Sotalol

Supraventricular Arrhythmias

Unsustained Ventricular Arrhythmias

Sustained Ventricular Arrhythmias

Adverse Effects

Summary

Source Information

From the Department of Cardiology, University Hospital, Freiburg, Germany (S.H.H.), and the Department of Pharmacology and Medicine, Georgetown University, Washington, D.C. (R.L.W.).

Address reprint requests to Dr. Hohnloser at University Hospital, Dept. of Cardiology, Hugstetterstr. 55, 79106 Freiburg, Germany.

References

This article has been cited by other articles:

• Connolly, S. J., Dorian, P., Roberts, R. S., Gent, M., Bailin, S., Fain, E. S., Thorpe, K., Champagne, J., Talajic, M., Coutu, B., Gronefeld, G. C., Hohnloser, S. H., for the Optimal Pharmacological Therapy in Cardiov, (2006). Comparison of {beta}-Blockers, Amiodarone Plus {beta}-Blockers, or Sotalol for Prevention of Shocks From Implantable Cardioverter Defibrillators: The OPTIC Study: A Randomized Trial. JAMA 295: 165-171 [Abstract] [Full Text]  
• Chang, G.-J., Su, M.-J., Kuo, S.-C., Lin, T.-P., Lee, Y.-S. (2006). Multiple Cellular Electrophysiological Effects of a Novel Antiarrhythmic Furoquinoline Derivative HA-7 [N-Benzyl-7-methoxy-2,3,4,9-tetrahydrofuro[2,3-b]quinoline-3,4-dione] in Guinea Pig Cardiac Preparations. J. Pharmacol. Exp. Ther. 316: 380-391 [Abstract] [Full Text]  
• Jost, N., Virag, L., Bitay, M., Takacs, J., Lengyel, C., Biliczki, P., Nagy, Z., Bogats, G., Lathrop, D. A., Papp, J. G., Varro, A. (2005). Restricting Excessive Cardiac Action Potential and QT Prolongation: A Vital Role for IKs in Human Ventricular Muscle. Circulation 112: 1392-1399 [Abstract] [Full Text]  
• Dorn, A., Hermann, F., Ebneth, A., Bothmann, H., Trube, G., Christensen, K., Apfel, C. (2005). Evaluation of a High-Throughput Fluorescence Assay Method for hERG Potassium Channel Inhibition. J Biomol Screen 10: 339-347 [Abstract]  
• Kailasam, R., Palin, C. A., Hogue, C. W. Jr (2005). Atrial Fibrillation After Cardiac Surgery: An Evidence-Based Approach to Prevention. SEMIN CARDIOTHORAC VASC ANESTH 9: 77-85 [Abstract]  
• Van Mieghem, C., Sabbe, M., Knockaert, D. (2004). The Clinical Value of the ECG in Noncardiac Conditions. Chest 125: 1561-1576 [Abstract] [Full Text]  
• Oudijk, M. A., Ruskamp, J. M., Ververs, F. F. T., Ambachtsheer, E. B., Stoutenbeek, P., Visser, G. H. A., Meijboom, E. J. (2003). Treatment of fetal tachycardia with sotalol: transplacental pharmacokinetics and pharmacodynamics. J Am Coll Cardiol 42: 765-770 [Abstract] [Full Text]  
• Forlani, S., De Paulis, R., de Notaris, S., Nardi, P., Tomai, F., Proietti, I., Ghini, A. S., Chiariello, L. (2002). Combination of sotalol and magnesium prevents atrial fibrillation after coronary artery bypass grafting. Ann. Thorac. Surg. 74: 720-726 [Abstract] [Full Text]  
• Biffi, M, Boriani, G, Bartolotti, M, Bacchi Reggiani, L, Zannoli, R, Branzi, A (2002). Atrial fibrillation recurrence after internal cardioversion: prognostic importance of electrophysiological parameters. Heart 87: 443-448 [Abstract] [Full Text]  
• Zhou, S., Cao, J.-M., Ohara, T., KenKnight, B. H., Chen, L. S., Karagueuzian, H. S., Chen, P.-S. (2002). Torsade de Pointes and Sudden Death Induced by Thiopental and Isoflurane Anesthesia in Dogs with Cardiac Electrical Remodeling. J CARDIOVASC PHARMACOL THER 7: 39-43 [Abstract]  
• Klingenheben, T., Gronefeld, G., Li, Y.-G., Hohnloser, S. H. (2001). Effect of metoprolol and d,l-sotalol on microvolt-level T-wave alternans: Results of a prospective, double-blind, randomized study. J Am Coll Cardiol 38: 2013-2019 [Abstract] [Full Text]  
• Mazur, A., Anderson, M. E., Bonney, S., Roden, D. M. (2001). Pause-dependent polymorphic ventricular tachycardia during long-term treatment with dofetilide: A placebo-controlled, implantable cardioverter-defibrillator-based evaluation. J Am Coll Cardiol 37: 1100-1105 [Abstract] [Full Text]  
• Lande, G., Kyndt, F., Baro, I., Chabannes, D., Boisseau, P., Pony, J.-C., Escande, D., Le Marec, H. (2001). Dynamic analysis of the QT interval in long QT1 syndrome patients with a normal phenotype. Eur Heart J 22: 410-422 [Abstract]  
• Kochiadakis, G. E., Kanoupakis, E. M., Kalebubas, M. D., Igoumenidis, N. E., Vardakis, K. E., Mavrakis, H. E., Vardas, P. E. (2001). Sotalol vs metoprolol for ventricular rate control in patients with chronic atrial fibrillation who have undergone digitalization: a single-blinded crossover study. Europace 3: 73-79 [Abstract]  
• Merot, J., Probst, V., Debailleul, M., Gerlach, U., Moise, N. S., Le Marec, H., Charpentier, F. (2000). Electropharmacological characterization of cardiac repolarization in German shepherd dogs with an inherited syndrome of sudden death: abnormal response to potassium channel blockers. J Am Coll Cardiol 36: 939-947 [Abstract] [Full Text]  
• Evrard, P., Gonzalez, M., Jamart, J., Malhomme, B., Blommaert, D., Eucher, P., Installe, E. (2000). Prophylaxis of supraventricular and ventricular arrhythmias after coronary artery bypass grafting with low-dose sotalol. Ann. Thorac. Surg. 70: 151-156 [Abstract] [Full Text]  
• Oudijk, M. A., Michon, M. M., Kleinman, C. S., Kapusta, L., Stoutenbeek, P., Visser, G. H. A., Meijboom, E. J. (2000). Sotalol in the Treatment of Fetal Dysrhythmias. Circulation 101: 2721-2726 [Abstract] [Full Text]  
• Pacifico, A., Hohnloser, S. H., Williams, J. H., Tao, B., Saksena, S., Henry, P. D., Prystowsky, E. N., The d,l-Sotalol Implantable Cardioverter-Defibrill, (1999). Prevention of Implantable-Defibrillator Shocks by Treatment with Sotalol. NEJM 340: 1855-1862 [Abstract] [Full Text]  
• Podrid, P. J. (1999). Redefining the Role of Antiarrhythmic Drugs. NEJM 340: 1910-1912 [Full Text]  
• Rizza, C., Valderrabano, M., Singh, B. N. (1999). Recurrent Torsades de Pointes After Sotalol Therapy for Symptomatic Paroxysmal Atrial Fibrillation in a Patient with End-Stage Renal Disease. J CARDIOVASC PHARMACOL THER 4: 129-134 [Abstract]  
• Adamson, P. B., Vanoli, E., Hull, S. S., Foreman, R. D., Schwartz, P. J. (1998). Antifibrillatory efficacy of ersentilide, a novel {beta}-adrenergic and Ikr blocker, in conscious dogs with a healed myocardial infarction. Cardiovasc Res 40: 56-63 [Abstract] [Full Text]  
• Eckman, M. H., Falk, R. H., Pauker, S. G. (1998). Cost-effectiveness of Therapies for Patients With Nonvalvular Atrial Fibrillation. Arch Intern Med 158: 1669-1677 [Abstract] [Full Text]  
• Chung, M. K., Schweikert, R. A., Wilkoff, B. L., Niebauer, M. J., Pinski, S. L., Trohman, R. G., Kidwell, G. A., Jaeger, F. J., Morant, V. A., Miller, D. P., Tchou, P. J. (1998). Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required?: yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications. J Am Coll Cardiol 32: 169-176 [Abstract] [Full Text]  
• Vos, M A, Golitsyn, S R, Stangl, K, Ruda, M Y, Van Wijk, L, Harry, J D, Perry, K T, Touboul, P, Steinbeck, G, Wellens, H J J (1998). Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. Heart 79: 568-575 [Abstract] [Full Text]  
• Lowe, M D, Stone, D L, Grace, A A (1998). Sotalol associated polymorphic ventricular tachycardia and coronary spasm. Heart 79: 518-520 [Abstract] [Full Text]  
• Grace, A. A., Camm, A. J. (1998). Quinidine. NEJM 338: 35-45 [Full Text]  
• (1996). Too many beta-blockers. DTB 34: 49-52 [Abstract] [Full Text]  
• (1996). The antiarrhythmic treatment of atrial fibrillation. DTB 34: 41-45 [Abstract] [Full Text]  
• Grace, A. A., Chien, K. R. (1995). Congenital Long QT Syndromes : Toward Molecular Dissection of Arrhythmia Substrates. Circulation 92: 2786-2789 [Full Text]  
• Holubarsch, C., Schneider, R., Pieske, B., Ruf, T., Hasenfuss, G., Fraedrich, G., Posival, H., Just, H. (1995). Positive and Negative Inotropic Effects of DL-Sotalol and D-Sotalol in Failing and Nonfailing Human Myocardium Under Physiological Experimental Conditions. Circulation 92: 2904-2910 [Abstract] [Full Text]  
• Hohnloser, S. H., Meinertz, T., Stubbs, P., Crijns, H. J.G.M., Blanc, J.-J., Rizzon, P., Cheuvart, B. (1995). Efficacy and Safety of d-Sotalol, a Pure Class III Antiarrhythmic Compound, in Patients With Symptomatic Complex Ventricular Ectopy : Results of a Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Finding Study. Circulation 92: 1517-1525 [Abstract] [Full Text]